GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 33 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,611,201 | -18.3% | 559,445 | +8.1% | 0.00% | – |
| Q2 2023 | $1,971,328 | +90.6% | 517,409 | -7.0% | 0.00% | – |
| Q1 2023 | $1,034,411 | -54.0% | 556,135 | -43.1% | 0.00% | – |
| Q4 2022 | $2,248,399 | -26.9% | 977,564 | +2.4% | 0.00% | – |
| Q3 2022 | $3,075,000 | -44.6% | 954,858 | -5.4% | 0.00% | – |
| Q2 2022 | $5,550,000 | +157.7% | 1,009,148 | +9.1% | 0.00% | – |
| Q1 2022 | $2,154,000 | -54.3% | 924,631 | +18.6% | 0.00% | – |
| Q4 2021 | $4,709,000 | -63.6% | 779,691 | -16.5% | 0.00% | – |
| Q3 2021 | $12,947,000 | +3.7% | 933,459 | -2.8% | 0.00% | – |
| Q2 2021 | $12,487,000 | -15.0% | 960,535 | +0.6% | 0.00% | – |
| Q1 2021 | $14,699,000 | – | 954,458 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |